Overview

Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

Multicenter, prospective, open-labeled, 2-arm, randomized non-comparative (2:1) phase II trial assessing the efficacy of lurbinectedin in association with durvalumab

Phase:

Phase 2

Details

Lead Sponsor:

Institut Bergonié

Collaborators:

AstraZeneca
PharmaMar

Treatments:

Carboplatin
Durvalumab
Etoposide